-
12 June 2019
-
12 June 2019
Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions...
-
30 July 2020
-
30 July 2020
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am enco...
-
18 April 2019
-
18 April 2019
-
25 February 2019
-
25 February 2019
-
14 May 2019
-
14 May 2019
-
19 July 2018
-
19 July 2018
Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients
Ipsen Innovation Center – BioLabs to be located in Ipsen’s new and third global hub in the heart of Cambridge, Massachusetts...
-
04 July 2018
-
04 July 2018
-
14 February 2019
-
14 February 2019
Ipsen enregistre des résultats solides en 2018 et anticipe une nouvelle année de croissance des ventes et des résultats en 2019
Paris (France), le 14 Février 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a publié aujourd’hui ses résultats financiers pour l’année 2018....